SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump For President

The price of TRUMP CRYPTO is volatile as traders debate its potential, with some citing exhaustion of sellers while others point to corruption and call it a scam. Community members are expressing strong opinions, with some predicting a short squeeze and others anticipating a crash. Broader market factors and political events seem to be influencing the coin's movements.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending as investors react to its new NFL partnership, with some questioning the long-term impact and target audience fit, while others see potential for growth, especially with college-aged women. Community members are actively debating the significance of the deal and the company's overall direction, as well as the impact of analyst ratings. There's also discussion around potential manipulation and short squeezes in the stock.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

UAMY is trending due to discussions around a potential acquisition deal falling through, leading to price volatility. The community is debating the implications of this failed deal, particularly regarding the company's future prospects and potential government support, in light of its position in the antimony market amid ongoing concerns about supply chain independence from China. Traders are also actively discussing technical analysis, potential entry points, and the stock's overall long-term value.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending due to its entrance into the AI chip market, highlighted by the launch of new AI200 and AI250 chips aimed at data centers, positioning it as a competitor to Nvidia and AMD. Community discussions revolve around the potential impact of these chips, particularly their power efficiency and customer base, with some analysts expressing skepticism about revenue projections. The move signifies Qualcomm's diversification beyond mobile chips into the growing AI infrastructure sector.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is trending due to a pause in two Phase 3 trials of its gene-editing therapy, nex-z, following a patient hospitalization with liver problems, causing a significant stock drop. The community is debating the severity of the setback, with some viewing it as a buying opportunity due to the company's long-term potential and strong pipeline, while others express concern about the program's future. Discussions also include the impact on the broader gene-editing sector and comparisons to similar situations with other companies.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies is trending as investors discuss its potential role in the AI revolution, particularly highlighting its network infrastructure and a recent expansion of its Internet On-Demand service. Community members are weighing in on the company's prospects, with many focused on upcoming earnings and potential government contracts. There's considerable discussion around Lumen's Palantir partnership and speculation about further upside.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community rallies around a potential breakout, fueled by the optimistic "WAGMI" (We Are All Gonna Make It) sentiment. Discussions revolve around key resistance levels and the possibility of a Solana ETF, while some traders are also watching meme coins built on Solana, such as SLAP and WAGMI.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is trending as community members highlight staking rewards and IRL partnerships, including MMA fighter Karolina Arm. The community emphasizes the project's strong team and growing recognition within the crypto space. Discussions also focus on $SLAP's potential as a meme coin with real-world utility.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It also operates the Nichols Ranch, Alta Mesa, and White Mesa Mill projects. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels ($UUUU) is trending as investors discuss its potential role in securing a U.S.-based rare earth supply chain, particularly in light of geopolitical tensions with China and a recent joint venture in Australia. The community is also closely watching for potential government contracts and discussing high call option activity, suggesting possible insider knowledge or a significant upcoming catalyst. Some traders express concerns about stock dilution and the company's path to profitability.

Project Nema is a research initiative enhancing AI memory and companionship by integrating the C. elegans neural connectome with a large language model (LLM). The LLM translates human language to interact with the worm's simulated brain, addressing LLMs' lack of persistent emotional or psychological states beyond context windows. This creates a stable, evolving neural state that retains history across sessions. For example, user inputs like "good morning Nema" fetch state and history for processing. Utilities include companionship, where Nema acts as the LLM's "soul" for long-term personality building, and dynamic adaptation mimicking life. It also aims to boost LLM outputs via extended memory. The project involves user management and visualizations.

NEMA LAB

NEMA is trending as discussions highlight its AI utility and migration from the WORM project, with community members emphasizing its potential and unique technology. The migration is seen as a catalyst, with many believing NEMA can surpass WORM's previous market cap due to its added utility and 'intelligence'. It's part of a broader conversation around AI-driven crypto projects on the SOL network.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Qualcomm shares were up more than 11% in Monday’s midday session after the company unveiled two AI accelerator chips.</li><li>Intellia Therapeutics declined by more than 44% after the company announced a temporary pause in patient dosing and screening for two of its late-stage trials.</li><li>Avidity Biosciences shares were up nearly 42% in Monday’s midday trade after Novartis AG (NVS) agreed to acquire the former for $12 billion.</li></ul>U.S. equities surged in Monday’s midday trade after trade tensions with China cooled down after officials of the two countries met over the weekend.President Donald Trump expressed optimism about striking a deal with China. “I've got a lot of respect for President Xi, and I think we're going to come away with a deal. We have China coming and its going to be very interesting,” he told reporters aboard Air Force One, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.reuters.com/world/asia-pacific/trump-says-he-might-sign-final-tiktok-deal-thursday-2025-10-27/">report</a> by Reuters.President Trump is scheduled to meet his Chinese counterpart, President Xi Jinping, on Thursday.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, was up 0.94% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq 100 index, rose 1.56%. The&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust</a> (DIA), which tracks the Dow Jones Industrial Average, gained 0.42%.<h2 class="st-heading-2">Here are the top stocks making the biggest moves in Monday’s midday trade:</h2><a href="https://stocktwits.com/symbol/QCOM">Qualcomm Inc. (QCOM)</a>Qualcomm shares were up more than 11% in Monday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/qcom-stock-jumps-after-company-launches-ai-chips-to-take-on-amd-nvidia/cLG0OGnR3M6">unveiled</a> two artificial intelligence (AI) accelerator chips, the AI200 and AI250, aimed at enterprise and cloud customers.<a href="https://stocktwits.com/symbol/QCOM">QCOM stock</a> is up 22% year-to-date.<a href="https://stocktwits.com/symbol/TSLA">Tesla Inc. (TSLA)</a>Tesla shares gained nearly 6% in Monday’s midday trade. Cantor Fitzgerald hiked its price target on the stock to $510 from $355, while maintaining an ‘Overweight’ rating, according to TheFly. The firm cited better-than-expected third-quarter (Q3) revenue, gross margin, and free cash flow.<a href="https://stocktwits.com/symbol/TSLA">TSLA stock</a> is up 14% year to date.<a href="https://stocktwits.com/symbol/NTLA">Intellia Therapeutics Inc. (NTLA)</a>Intellia Therapeutics declined over 44% in Monday’s midday session after the company&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-ntla-stock-slump-pre-market-today/cLG07OdR3Ms">announced</a> a temporary pause in patient dosing and screening for two of its late-stage trials for Nex-z after a patient was hospitalized.<a href="https://stocktwits.com/symbol/NTLA">NTLA stock</a> is up 24% year to date.<a href="https://stocktwits.com/symbol/RNA">Avidity Biosciences Inc. (RNA)</a>Avidity Biosciences shares were up nearly 42% in Monday’s midday trade after Novartis AG (NVS) agreed to acquire the former for $12 billion. The deal offers Avidity investors $72 per share, a 46% premium over the stock’s Friday closing price.<a href="https://stocktwits.com/symbol/RNA">RNA stock</a> is up 141% year to date.<a href="https://stocktwits.com/symbol/DYN">Dyne Therapeutics Inc. (DYN)</a>Dyne Therapeutics shares were up 41% in Monday’s midday session following the acquisition of Avidity by Novartis. Analysts at Morgan Stanley&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/dyne-therapeutics-stock-soars-after-rival-avidity-biosciences-gets-acquired-by-novartis/cLG0X2XR3u7">stated</a> that the Avidity acquisition provides positive read-through to Dyne, as reported by TheFly. Both Avidity and Dyne are advancing therapies for rare muscle diseases, myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy.<a href="https://stocktwits.com/symbol/DYN">DYN stock</a> is up 3% year to date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-stock-hits-all-time-high-market-capitalization-inches-toward-4-trillion/cLG0gUVR3u9">Apple Stock Hits All-Time High, Market Capitalization Inches Toward $4 Trillion</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Qualcomm, Tesla, Intellia Therapeutics, Avidity Biosciences, Dyne Therapeutics: Stocks Making The Biggest Moves Today

Qualcomm shares were up more than 11% in Monday’s midday session after the company unveiled two AI accelerator chips.

Equity

<ul class="summary-bullets"><li>Intellia said that it has temporarily paused patient dosing and screening for two of its late-stage trials for Nex-z.</li><li>The decision follows a report on October 24 of heightened liver transaminases and increased total bilirubin in a patient who was dosed with Nex-z in a trial.</li><li>The patient is being closely monitored and receiving medical intervention, the company said. &nbsp;</li></ul>Intellia Therapeutics, Inc. (NTLA) on Monday said that it has temporarily paused patient dosing and screening for two of its late-stage trials for Nex-z after a patient was hospitalized.The company has paused dosing in a trial that enrolled patients with transthyretin amyloidosis with cardiomyopathy and another that enrolled patients with polyneuropathy. Transthyretin amyloidosis with cardiomyopathy is a severe and progressive heart failure caused by the buildup of misfolded amyloid fibrils, derived from the transthyretin protein, in the heart muscle. Transthyretin amyloidosis with polyneuropathy, meanwhile, is a progressive, multisystem disease caused by the buildup of abnormal proteins in the body's organs and tissues.&nbsp;<h2 class="st-heading-2">Why The Pause?</h2>The decision follows a report on October 24 of heightened liver transaminases and increased total bilirubin in a patient who was dosed with Nex-z in a trial, raising concerns of drug-induced liver injury. The patient was dosed with Nex-z on September 30.The hospitalized patient is being closely monitored and receiving medical intervention, the company said.<h2 class="st-heading-2">What Are The Company’s Plans?</h2>Meanwhile, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174462/0/en/Intellia-Therapeutics-Provides-Update-on-MAGNITUDE-Clinical-Trials-of-Nexiguran-Ziclumeran-nex-z.html">said</a> it is consulting with experts, considering potential risk mitigation strategies, and engaging with regulatory authorities.<blockquote>“In line with our commitment to patient safety, we have taken immediate action to temporarily pause enrollment in MAGNITUDE and MAGNITUDE-2 as we investigate this recent event. As we focus on ensuring the health of this patient, we also are engaging with regulatory authorities and other stakeholders globally to develop a strategy to resume enrollment as soon as appropriate.”&nbsp; – John Leonard, CEO, Intellia Therapeutics</blockquote>Nex-z or Nexiguran Ziclumeran is a therapy based on gene editing technology. It is designed to inactivate the TTR gene that encodes the transthyretin protein. As of Monday, more than 700 patients have been enrolled in the two trials in which Intellia has paused dosing, and over 450 have already been dosed with Nex-z.Shares of the company slumped 43% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NTLA">NTLA stock</a> soared from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘high’ levels.NTLA stock has more than doubled this year and gained about 57% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/bbio-stock-soars-after-experimental-drug-shows-improvement-in-inherited-muscle-disorder-in-late-stage-trial/cLG04ksR3Mm">BBIO Stock Soars After Experimental Drug Shows Improvement In Inherited Muscle Disorder In Late-stage Trial</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA. (Photo by: Spencer Grant/GHI/UCG/Universal Images Group via Getty Images)

Why Did NTLA Stock Tumble 43% Pre-Market Today?

Intellia said that it has temporarily paused patient dosing and screening for two of its late-stage trials for Nex-z.

Can NTLA's In Vivo Pipeline Aid Long-Term Growth Amid Competition?

Intellia banks on its late-stage gene-editing therapies, lonvo-z and nex-z, that could define its long-term growth phase in the gene editing space.

Take the Zacks Approach to Beat the Market: UnitedHealth, Ovid, Micron in Focus

Zacks' winning streak continues as UnitedHealth, Ovid and Micron deliver standout gains across key model portfolios.

Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock?

Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Intellia Therapeutics (NTLA) Upgraded to Buy: Here's What You Should Know

Intellia Therapeutics (NTLA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Wall Street Analysts Predict a 63.7% Upside in Intellia Therapeutics (NTLA): Here's  What You Should Know

The consensus price target hints at a 63.7% upside potential for Intellia Therapeutics (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Is Intellia Therapeutics (NTLA) Outperforming Other Medical Stocks This Year?

Here is how Intellia Therapeutics, Inc. (NTLA) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.

Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus

Amneal Pharmaceuticals, Leidos and Vishay Precision stand out as Zacks highlights amid market volatility and shifting rate expectations.

Take the Zacks Approach to Beat the Market: LendingTree, AutoZone, J&J in Focus

Zacks highlights winners like LendingTree, AutoZone, and Johnson & Johnson as its proven stock-picking strategies continue to shine.

Will Meta ($META) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Meta Platforms Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

NTLA
Intellia Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NTLA News

NTLAIntellia Therapeutics Inc